During the first six months of 2025, King Faisal Specialist Hospital and Research Centre (KFSH) in Riyadh emerged as a pivotal player in clinical research in Saudi Arabia, conducting 48% of all registered clinical trials. This achievement underscores the hospital’s expanding influence in advanced healthcare development and clinical research. The hospital’s research activities are supported by a multidisciplinary team comprising investigators, research nurses, pharmacists, coordinators, data specialists, and regulatory and ethics experts, all working collaboratively to advance clinical studies from initial planning through to patient recruitment and data management.
Established in 2020, KFSH’s centralized Clinical Trials service plays a crucial role in coordinating research efforts by its clinicians and investigators. This service oversees feasibility assessments, study activation, trial operations, patient recruitment, investigational medicines, and regulatory compliance, ensuring the integrity and quality of the research process. In the first half of 2025, KFSH recorded 104 active clinical trials, with 80 new studies initiated across diverse medical fields such as cancer, cardiovascular disease, autoimmune and musculoskeletal conditions, dermatology, gastroenterology, liver disease, and endocrine and metabolic disorders. These studies not only offer patients access to novel treatment options but also contribute to the generation of clinical evidence tailored to Saudi Arabia’s healthcare needs.
Among the significant advancements at KFSH is the initiation of a Phase I clinical trial for relapsed acute lymphoblastic leukemia, utilizing locally manufactured genetically engineered CAR-T cells. This trial marks a milestone in cell therapy research, integrating local scientific expertise with advanced biomanufacturing and specialized clinical care within a single research framework. Such developments highlight the hospital’s commitment to pioneering innovative treatment options.
KFSH’s robust clinical-trial infrastructure also facilitates its involvement in intricate international studies, fostering collaborations with multinational research partners. The hospital’s governance and clinical capabilities ensure adherence to patient safety, ethical standards, data quality, and regulatory compliance, creating a solid foundation for global research partnerships. KFSH is set to showcase its clinical research and healthcare innovation strategies at the C3 US NYC Davos of Healthcare Summit 2026 in New York City on September 14.
Recognized among leading academic medical centers worldwide and in the Middle East, KFSH has gained international acclaim for its healthcare brand and has been featured in global hospital rankings. The hospital’s achievements reflect its dedication to advancing clinical research and healthcare innovation, cementing its role as a leader in the field.
Legal Disclaimer:
The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.